WO2002086512A2 - Haemoglobin assay - Google Patents

Haemoglobin assay Download PDF

Info

Publication number
WO2002086512A2
WO2002086512A2 PCT/GB2002/001664 GB0201664W WO02086512A2 WO 2002086512 A2 WO2002086512 A2 WO 2002086512A2 GB 0201664 W GB0201664 W GB 0201664W WO 02086512 A2 WO02086512 A2 WO 02086512A2
Authority
WO
WIPO (PCT)
Prior art keywords
reagent
haemoglobin
kit
conjugate
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001664
Other languages
French (fr)
Other versions
WO2002086512A3 (en
Inventor
Jostein Holtlund
Kerstin BERNSTRÖM
Ellen Dworsky
Lise Corneliussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axis Shield ASA
Original Assignee
Axis Shield ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002583989A priority Critical patent/JP4184806B2/en
Priority to US10/474,505 priority patent/US7374943B2/en
Priority to DK02713068T priority patent/DK1381869T3/en
Priority to DE60227935T priority patent/DE60227935D1/en
Priority to EP02713068A priority patent/EP1381869B1/en
Priority to CA002441929A priority patent/CA2441929C/en
Application filed by Axis Shield ASA filed Critical Axis Shield ASA
Priority to AU2002244858A priority patent/AU2002244858B2/en
Publication of WO2002086512A2 publication Critical patent/WO2002086512A2/en
Publication of WO2002086512A3 publication Critical patent/WO2002086512A3/en
Priority to NO20034687A priority patent/NO332622B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G01N33/683—Total protein determination, e.g. albumin in urine involving metal ions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin

Definitions

  • This invention relates to improvements in and relating to methods of assaying for glycated haemoglobin.
  • Proteins in solution in body fluids are continually- subject to glycosylation processes. Glucose reacts with the proteins by non-enzymatic reactions to form glycoproteins, and in many cases the level of glycoprotein formation is proportional to the glucose concentration in the body fluid in question. For proteins not initially synthesized as glycoproteins, the fraction of a protein present in glycated form is therefore a function of the life-time of the protein in the organism and the glucose concentrations to which the protein has been exposed.
  • the amount of a protein present in glycosylated form gives an indication of the organism's control of glucose concentration over longer periods of time .
  • Erythrocytes red blood cells
  • Erythrocytes have a mean lifetime of approximately 120 days and contain large amounts of haemoglobin.
  • the fraction of erythrocyte haemoglobin in glycosylated form is thus a good measure of the control of the disease in patients with diabetes mellitus, and is a function of the glucose concentrations in the blood of the patient in the weeks prior to the blood sampling.
  • US-A-5242842 it was proposed to assay for glycosylated haemoglobin using as a reporter-labelled reagent a boronic acid conjugate, e.g.
  • the anionic B (OH) ⁇ 3 component of the reagent binds to the cis-diol groups of the glycosylated haemoglobin so labelling the glycosylated haemoglobin with the reporter label (e.g. RESOS or FITC) .
  • the reporter label e.g. RESOS or FITC
  • a diagnostic assay for glycated (i.e. glycosylated) haemoglobin using this system is available commercially from Axis-Shield Pic as the NycoCard ® HbAlc test.
  • a slightly alkaline aqueous reagent solution is mixed with a blood sample and the mixture is applied to a porous membrane which is rinsed before light reflectance by the membrane (i.e. by the haemoglobin trapped on the membrane) is determined.
  • the reagent solution comprises a surfactant (to lyse the erythrocytes and release haemoglobin) , XC-DAPOL-CPBA to bind to glycated haemoglobin and zinc ions to precipitate the haemoglobin.
  • the precipitated haemoglobin, both glycated and non-glycated is caught by the membrane while other glycated proteins and excess boronic acid conjugate are washed off the membrane by the rinsing step.
  • the results for this assay however can vary with the storage time of the reagent, becoming unreliable if it is stored for about 6 months or more. Since a clinical laboratory may have test kits of varying ages, there is thus a need to increase the reproducible accuracy of a boronic acid conjugate-based glycated haemoglobin assay.
  • the invention provides a kit for a glycated haemoglobin assay, said kit comprising: a porous membrane capable of retaining precipitated haemoglobin; a first reagent comprising zinc ions in aqueous basic solution or comprising a water-soluble zinc compound; a second reagent comprising a chromophore-boronic acid conjugate; and optionally, an aqueous washing reagent; wherein at least one of the first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second reagent if liquid is acidic.
  • the second reagent in the kit of the invention may be a solution or a dried or solvent-free material.
  • This reagent preferably comprises at least part of the surfactant.
  • the solvent where the reagent is liquid, may be water or a water-miscible organic solvent, e.g. an alcohol, ether, ketone, amide, sulphoxide, etc., or a mixture of two or more of these. Preferred examples of solvents are water, methanol, DMSO and formamide.
  • the reagent preferably includes an acid (e.g. citric acid) and preferably has a pH below 6, more preferably below 5, if it is liquid.
  • the reagent is dried or solvent- free it is especially preferred that it be prepared by drying a solution for which the solvent is water, methanol, or methanol and water (preferably up to 70% by volume methanol, e.g. at least 20%, for example 30 to 70%) .
  • the use of water as the solvent is particularly preferred. It has been surprisingly been found that drying such a solution containing the boronic acid conjugate and surfactant, e.g. by evaporation, leaves an oily residue which is more rapidly dissolved in water than the conjugate or surfactant alone.
  • a methanol/water system it is found that the residue is capable of giving more uniform coating to a surface than is the case with methanol alone.
  • a water-soluble macromolecule which does not interfere with the haemoglobin assay eg a protein such as albumin (for example bovine serum albumin)
  • albumin for example bovine serum albumin
  • the inclusion of such a macromolecule is also beneficial when the second reagent is in liquid form as it reduces incidence of conjugate precipitation.
  • its inclusion in either the first reagent or the second reagent or both has been found to shorten the time required for uniform mixing of the first and second reagents.
  • either or both of the first and second reagents contain such a macromolecular compound, in particular BSA at a concentration of up to 1% w/v, especially 0.025 to 0.3% w/v, more especially 0.05 to 0.1% w/v.
  • the boronic acid conjugate may for example be any of the chromophore-boronic acid conjugates described in US-A-5242842, US-A-5631364 and US-A-5739318 ; however XC- DAPOL-CPBA is preferred.
  • the surfactant used in the reagents may be any surfactant capable of lysing erythrocyt s, e.g. deoxycholates, Tritons and Tweens; however non-ionic surfactants such as Tritons, in particular Triton X-100 are preferred.
  • the first reagent may be a basic aqueous solution or may be dissolvable in water or an aqueous base to produce a basic aqueous solution. In the second case it may be a dried aqueous solution which simply requires reconstitution with water.
  • the first reagent preferably also comprises surfactant, and may contain other optional components, for example inorganic salts (e.g. sodium or magnesium chloride and sodium azide) , glycine and buffering compounds.
  • the zinc is preferably introduced as an inorganic salt, e.g. the chloride.
  • the primary solvent is preferably water, but other water-miscible solvents may be present.
  • the reagent's pH is basic, preferably weakly basic, e.g. 7.1 to 8.5, preferably 8.0 to 8.2, especially about 8.1. The pH however should be such as to make the mixture of the first and second reagents basic when the two are combined.
  • the first reagent preferably contains 5 to 30mM, especially 7 to 20mM zinc, and 0.05 to 0.22 w/v surfactant and is preferably buffered to pH 7.8 to 8.2.
  • the second reagent if an aqueous liquid preferably contains 0.15 to 0.75 mg/g, especially 0.20 to 0.50 mg/g conjugate, and 0.05 to 0.25% w/v, especially 0.1 to 0.2% w/v, surfactant, and 5 to 20% v/v, especially 10 to 15% v/v water-miscible organic solvent (e.g formamide or DMSO) , and if dried it is preferably formed from an aqueous solution containing 0.1 to 0.5 mg/mL, especially 0.1 to 0.4 mg/mL.
  • aqueous liquid preferably contains 0.15 to 0.75 mg/g, especially 0.20 to 0.50 mg/g conjugate, and 0.05 to 0.25% w/v, especially 0.1 to 0.2% w/v, surfactant, and 5 to 20%
  • the washing reagent is conveniently an aqueous buffer, e.g. Hepes .
  • a particularly suitable washing reagent comprises 50 mM morpholine, 200 mM NaCl, 0.5% w/v Triton-X-100, 0.1% w/v glycerol, 0.05% w/v NaN 3 , pH 9.1.
  • the membrane used in the kit of the invention can be any suitably pore-sized membrane; however it is conveniently a glass fibre or borosilicate filter or a cellulosic membrane, e.g. with a "pore size" of 0.5 to 1.5 ⁇ m, especially 0.8 to 1.0 ⁇ m.
  • an absorbent layer e.g. a cellulosic layer or a polyether sulphone layer, is disposed against the membrane on the surface remote from the sample application surface and this will serve to draw the sample and reagents through the membrane by capillary action.
  • the first and second reagents are preferably disposed in a two chamber container with a frangible membrane separating the chambers .
  • This may for example take the form of a breakable (e.g. glass) container disposed inside a flexible container. Breaking the frangible membrane separator (e.g. the wall of a glass vial) allows the two reagents to be mixed before being brought into contact with the blood sample.
  • the second reagent is a dried material, it is preferably present in the kit coated onto the base and/or walls of a container or a stopper.
  • the first reagent can be filled into the second reagent's container to bring the conjugate into solution for the assay or a stopper coated with dried second reagent can be placed in the neck of a vial (eg a prefilled vial) of liquid first reagent.
  • the second reagent if liquid can be used correspondingly to bring a dried first reagent into solution for use in the assay.
  • the invention also provides a method for assaying a blood sample for glycated haemoglobin, said method comprising contacting a blood sample with a surfactant capable of lysing erythrocytes, a chromophore-boronic acid conjugate, and zinc ions in aqueous solution, allowing the sample to incubate, passing the incubated sample through a porous membrane capable of retaining precipitated haemoglobin, flushing the membrane to remove conjugate not coupled to haemoglobin, measuring light reflected from the membrane at wavelengths at which haemoglobin and the conjugate respectively absorb light, and comparing the measured reflected light intensities whereby to provide a indication (e.g.
  • conjugate and zinc ions are brought together by combining a first reagent comprising zinc ions in aqueous basic solution and a second reagent comprising a chromophore-boronic acid conjugate wherein at least one of said first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second regent if liquid is acidic.
  • kit of the invention may be used in the assay method of the invention.
  • the invention provides a water-soluble material produced by drying a solution (e.g. an aqueous, alkanolic or aqueous-alkanolic solution) of an unsaturated cyclic organic acid (e.g. one having a molecular weight of 500 to 1500D, for example a boronic acid conjugate) and a surfactant (e.g. a non-ionic surfactant, especially a Triton) .
  • a solution may of course contain further solutes which would likewise be released when the material is contacted with water.
  • a vacuum drying oven or a freeze-drier with a programmable vacuum controller can be used.
  • the apparatus should be set to approach a pressure of 7-10 mbar within 40-65 minutes.
  • the setting will vary. The settings may thus be varied so as to produce an even film of dried material on the plastic walls.
  • the first reagent comprises :
  • the reagent is prepared by mixing ImL IM Hepes, 0.25 mL IM glycine, 2mL H 2 0, 0.09 mL IM ZnCl 2 , 0.15 mL IM MgCl 2 , 0.4 mL 5M NaCl, 0.075 mL 10% Triton X-100 and 0.025 mL
  • the first reagent may alternatively be made as follows: 24.6 mg zinc chloride is dissolved in 2.5 mL water. 233.8 mg sodium chloride, 61 mg magnesium chloride hexahydrate, 0.05 mL 10% sodium azide and 0.1 mL 10% Triton X-100 are dissolved in 2.5 mL water. The two solutions are then combined. 476.6 mg HEPES and 37.6 mg glycine are dissolved in 1.5 mL water and 0.4 mL 5M sodium hydroxide. This HEPES solution is then added to the zinc and Triton X-100 solution and the pH is adjusted to 8.1 and the volume to 10 mL.
  • the second reagent comprises:
  • the reagent is prepared by mixing 0.11 mL formamide, 0.52 mL XC-DAPOL-CPBA (3.15 g/L in formamide) and water to 5mL. DMSO may be used in place of formamide.
  • 100 ⁇ L of the first reagent is mixed with 100 ⁇ L of the second reagent .
  • the mixture is added to 5 ⁇ L blood and allowed to incubate for 2 minutes.
  • a 25 ⁇ L aliquot is then placed on a glass fibre filter.
  • 25 ⁇ L of a washing solution pH 9.1 (Example 4) is added and the result is read on a NycoCard ® reader at 632 and 476- nm.
  • the first reagent comprises:
  • the reagent is prepared by mixing 1 mL IM Hepes, 0.25 mL 1 M glycine, 2 mL H 2 0, 0.09 mL IM ZnCl 2 , 0.15 mL IM
  • the first reagent may alternatively be made as follows: 12.3 mg zinc chloride is dissolved in 2.5 mL water. 116.9 mg sodium chloride, 30.5 mg magnesium chloride hexahydrate, 0.05 mL 10% sodium azide and 0.1 mL 10% Triton X-100 are dissolved in 2.5 mL water. The two solutions are then combined. 238.3 mg HEPES and 18.8 mg glycine are dissolved in 1.5 mL water and 0.2 mL 5M sodium hydroxide. This HEPES solution is then added to the zinc and Triton X-100 solution and the pH is adjusted to 8.1 and the volume to 10 mL.
  • the solution precursor comprises
  • the solution precursor is prepared by dissolving XC- DAPOL-CPBA in methanol 0.36 mg/mL. 2 mL of this are mixed with 105 ⁇ L 10% Triton X-100, ImL water and 15 ⁇ L 0.1 M citric acid.
  • the solution precursor may alternatively comprise
  • Triton X-100 0.336% w/v Triton X-100 0.4-0.6 mM citric acid to pH 4.1
  • the solution precursor is prepared by dissolving XC- DAPOL-CPBA in methanol 2.5 mg/mL. 2 mL of the solution is mixed with 4.8 mL 0.7% Triton X-100 and 2 mL 0.5% w/v BSA is added and the pH is adjusted to .1 with 0.1 M citric acid (ca 50-60 ⁇ L) . Water is added to a volume of 10 mL. The amount of XC-DAPOL-CPBA used is adjusted to provide an optical density (OD) of 32.5 at 620 nm.
  • OD optical density
  • the first reagent comprises :
  • the BSA-containing solution referred to in Example 2 as the solution precursor is used in a liquid form.
  • the washing solution comprises
  • the solution is prepared by mixing the components, adjusting to pH 9.1 and adding water to achieve the desired concentration.
  • the materials for the assay are prepared as in Example 2 except that the solution precursor is prepared by dissolving the boronic acid conjugate in 0.5 mM NaOH to 0.25 mg/mL. This requires 10 to 30 minutes stirring. 2 mL of the solution is then mixed with 0.05 mL 10% Triton X-100 and stirred for a further 10 minutes. The pH is then reduced to about 4.5 by addition of 0.01 mL 0. IM citric acid. The assay is performed as in Example 2.
  • the materials for the assay are prepared as in Example 2 except that the solution precursor is prepared by dissolving the boronic acid in 10 mM NaOH to 2.5 mg/mL. 2 mL of this are mixed with 4.8 mL 0.7% w/v Triton X- 100. 2 mL 0.5% w/v BSA is added and the pH is adjusted to 4.1 with 0.1 M citric acid (50-60 ⁇ L) . Water is added to a volume of 10 mL. The quantity of conjugate used is adjusted to provide an optical density at 620 nm of 32.5. The assay is performed as in Example 2.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention provides a kit for a glycated haemoglobin assay, said kit comprising : a porous membrane capable of retaining precipitated haemoglobin; a first reagent comprising zinc ions in aqueous basic solution or comprising a water soluble zinc compound; a second reagent comprising a chromophore-boronic acid conjugate; and optionally, an aqueous washing reagent; wherein at least one of the first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second reagent if liquid is acidic.

Description

Haemoglobin Assay
This invention relates to improvements in and relating to methods of assaying for glycated haemoglobin.
Proteins in solution in body fluids are continually- subject to glycosylation processes. Glucose reacts with the proteins by non-enzymatic reactions to form glycoproteins, and in many cases the level of glycoprotein formation is proportional to the glucose concentration in the body fluid in question. For proteins not initially synthesized as glycoproteins, the fraction of a protein present in glycated form is therefore a function of the life-time of the protein in the organism and the glucose concentrations to which the protein has been exposed.
Unlike measurements of glucose concentrations in blood, plasma or urine, which only give information about the glucose concentration at the time of sampling, the amount of a protein present in glycosylated form gives an indication of the organism's control of glucose concentration over longer periods of time .
Erythrocytes (red blood cells) have a mean lifetime of approximately 120 days and contain large amounts of haemoglobin. The fraction of erythrocyte haemoglobin in glycosylated form is thus a good measure of the control of the disease in patients with diabetes mellitus, and is a function of the glucose concentrations in the blood of the patient in the weeks prior to the blood sampling. In US-A-5242842 (Axis) it was proposed to assay for glycosylated haemoglobin using as a reporter-labelled reagent a boronic acid conjugate, e.g. a conjugate of N- (resorufin-4-carbonyl)piperidine-4-carboxylic acid-N- hydroxysuccinimide ester (RESOS) or fluorescein isothiocyanate (FITC) with aminophenyl boronic acid.
The anionic B (OH) ~ 3 component of the reagent binds to the cis-diol groups of the glycosylated haemoglobin so labelling the glycosylated haemoglobin with the reporter label (e.g. RESOS or FITC) .
In US-A-5631364 (Axis) , a group of .particularly effective reporter-labelled boronic acid conjugates were described, including the xylene-cyanole-phenyl boronic acid conjugate referred to therein as XC-DAPOL-CPBA. The chromophore label gives this conjugate an absorption maximum at 616 nm (i.e. it is blue in colour) and the proportion of haemoglobin in a sample that is glycosylated can be determined by measuring sample absorbance at 616 nm and at 415 nm, where haemoglobin has an absorption maximum.
A diagnostic assay for glycated (i.e. glycosylated) haemoglobin using this system is available commercially from Axis-Shield Pic as the NycoCard® HbAlc test. In operation of this test a slightly alkaline aqueous reagent solution is mixed with a blood sample and the mixture is applied to a porous membrane which is rinsed before light reflectance by the membrane (i.e. by the haemoglobin trapped on the membrane) is determined. The reagent solution comprises a surfactant (to lyse the erythrocytes and release haemoglobin) , XC-DAPOL-CPBA to bind to glycated haemoglobin and zinc ions to precipitate the haemoglobin. The precipitated haemoglobin, both glycated and non-glycated is caught by the membrane while other glycated proteins and excess boronic acid conjugate are washed off the membrane by the rinsing step. The results for this assay however can vary with the storage time of the reagent, becoming unreliable if it is stored for about 6 months or more. Since a clinical laboratory may have test kits of varying ages, there is thus a need to increase the reproducible accuracy of a boronic acid conjugate-based glycated haemoglobin assay.
We have now found that the reliability of such assays can be improved if the boronic acid conjugate and the zinc are present in separate reagents in the assay kit. Thus viewed from one aspect the invention provides a kit for a glycated haemoglobin assay, said kit comprising: a porous membrane capable of retaining precipitated haemoglobin; a first reagent comprising zinc ions in aqueous basic solution or comprising a water-soluble zinc compound; a second reagent comprising a chromophore-boronic acid conjugate; and optionally, an aqueous washing reagent; wherein at least one of the first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second reagent if liquid is acidic.
The second reagent in the kit of the invention may be a solution or a dried or solvent-free material. This reagent preferably comprises at least part of the surfactant. The solvent, where the reagent is liquid, may be water or a water-miscible organic solvent, e.g. an alcohol, ether, ketone, amide, sulphoxide, etc., or a mixture of two or more of these. Preferred examples of solvents are water, methanol, DMSO and formamide. The reagent preferably includes an acid (e.g. citric acid) and preferably has a pH below 6, more preferably below 5, if it is liquid. If the reagent is dried or solvent- free it is especially preferred that it be prepared by drying a solution for which the solvent is water, methanol, or methanol and water (preferably up to 70% by volume methanol, e.g. at least 20%, for example 30 to 70%) . The use of water as the solvent is particularly preferred. It has been surprisingly been found that drying such a solution containing the boronic acid conjugate and surfactant, e.g. by evaporation, leaves an oily residue which is more rapidly dissolved in water than the conjugate or surfactant alone. Moreover, where a methanol/water system is used it is found that the residue is capable of giving more uniform coating to a surface than is the case with methanol alone. The results are even better when water alone is used as the solvent . It may be noted that it has long been known to be problematical to dry surfactant solutions with the result generally being a clumpy, porridge-like residue and this ability to produce a uniform, rapidly water- dispersible residue is most surprising.
The addition of a water-soluble macromolecule which does not interfere with the haemoglobin assay, eg a protein such as albumin (for example bovine serum albumin) , in the production of the second reagent in dry or solvent-free form has been found to be especially beneficial as the dried residue is found to be more uniform, especially when after long periods of storage. The inclusion of such a macromolecule is also beneficial when the second reagent is in liquid form as it reduces incidence of conjugate precipitation. Moreover its inclusion in either the first reagent or the second reagent or both has been found to shorten the time required for uniform mixing of the first and second reagents. As a result, it is preferred that either or both of the first and second reagents contain such a macromolecular compound, in particular BSA at a concentration of up to 1% w/v, especially 0.025 to 0.3% w/v, more especially 0.05 to 0.1% w/v.
The boronic acid conjugate may for example be any of the chromophore-boronic acid conjugates described in US-A-5242842, US-A-5631364 and US-A-5739318 ; however XC- DAPOL-CPBA is preferred.
The surfactant used in the reagents may be any surfactant capable of lysing erythrocyt s, e.g. deoxycholates, Tritons and Tweens; however non-ionic surfactants such as Tritons, in particular Triton X-100 are preferred. The first reagent may be a basic aqueous solution or may be dissolvable in water or an aqueous base to produce a basic aqueous solution. In the second case it may be a dried aqueous solution which simply requires reconstitution with water.
The first reagent preferably also comprises surfactant, and may contain other optional components, for example inorganic salts (e.g. sodium or magnesium chloride and sodium azide) , glycine and buffering compounds. The zinc is preferably introduced as an inorganic salt, e.g. the chloride. The primary solvent is preferably water, but other water-miscible solvents may be present. The reagent's pH is basic, preferably weakly basic, e.g. 7.1 to 8.5, preferably 8.0 to 8.2, especially about 8.1. The pH however should be such as to make the mixture of the first and second reagents basic when the two are combined.
The first reagent preferably contains 5 to 30mM, especially 7 to 20mM zinc, and 0.05 to 0.22 w/v surfactant and is preferably buffered to pH 7.8 to 8.2. The second reagent, if an aqueous liquid preferably contains 0.15 to 0.75 mg/g, especially 0.20 to 0.50 mg/g conjugate, and 0.05 to 0.25% w/v, especially 0.1 to 0.2% w/v, surfactant, and 5 to 20% v/v, especially 10 to 15% v/v water-miscible organic solvent (e.g formamide or DMSO) , and if dried it is preferably formed from an aqueous solution containing 0.1 to 0.5 mg/mL, especially 0.1 to 0.4 mg/mL. more especially 0.15 to 0.3 mg/mL conjugate, 0.1 to 0.5% w/v, especially 0.25 to 0.4% w/v surfactant, 0.2 to 0.6 M, especially 0.4 to 0.55. ,mM acid (e.g. citric acid), up to 70% v/v, preferably 0 or up to (e.g. 1% v/v upwards) to 50% v/v methanol, and preferably 0.025 to 0.3% w/v, especially 0.05 to 0.1%, BSA. The washing reagent is conveniently an aqueous buffer, e.g. Hepes . A particularly suitable washing reagent comprises 50 mM morpholine, 200 mM NaCl, 0.5% w/v Triton-X-100, 0.1% w/v glycerol, 0.05% w/v NaN3, pH 9.1.
The membrane used in the kit of the invention can be any suitably pore-sized membrane; however it is conveniently a glass fibre or borosilicate filter or a cellulosic membrane, e.g. with a "pore size" of 0.5 to 1.5 μm, especially 0.8 to 1.0 μm. Desirably an absorbent layer, e.g. a cellulosic layer or a polyether sulphone layer, is disposed against the membrane on the surface remote from the sample application surface and this will serve to draw the sample and reagents through the membrane by capillary action.
In the kit of the invention, the first and second reagents (where the second reagent is liquid) are preferably disposed in a two chamber container with a frangible membrane separating the chambers . This may for example take the form of a breakable (e.g. glass) container disposed inside a flexible container. Breaking the frangible membrane separator (e.g. the wall of a glass vial) allows the two reagents to be mixed before being brought into contact with the blood sample. Where the second reagent is a dried material, it is preferably present in the kit coated onto the base and/or walls of a container or a stopper. In this way the first reagent can be filled into the second reagent's container to bring the conjugate into solution for the assay or a stopper coated with dried second reagent can be placed in the neck of a vial (eg a prefilled vial) of liquid first reagent. The second reagent if liquid can be used correspondingly to bring a dried first reagent into solution for use in the assay.
Reagent containers in the kit as supplied should desirably be capped to prevent liquid loss or moisture ingress . In a further aspect, the invention also provides a method for assaying a blood sample for glycated haemoglobin, said method comprising contacting a blood sample with a surfactant capable of lysing erythrocytes, a chromophore-boronic acid conjugate, and zinc ions in aqueous solution, allowing the sample to incubate, passing the incubated sample through a porous membrane capable of retaining precipitated haemoglobin, flushing the membrane to remove conjugate not coupled to haemoglobin, measuring light reflected from the membrane at wavelengths at which haemoglobin and the conjugate respectively absorb light, and comparing the measured reflected light intensities whereby to provide a indication (e.g. a quantitative, semi-quantitative or qualitative indication) of the proportion of haemoglobin in the blood sample which is glycated, characterised in that said conjugate and zinc ions are brought together by combining a first reagent comprising zinc ions in aqueous basic solution and a second reagent comprising a chromophore-boronic acid conjugate wherein at least one of said first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second regent if liquid is acidic.
Clearly the kit of the invention may be used in the assay method of the invention.
As mentioned above, the combination of surfactant and conjugate is more readily water soluble than the surfactant or conjugate alone. Thus viewed from a further aspect the invention provides a water-soluble material produced by drying a solution (e.g. an aqueous, alkanolic or aqueous-alkanolic solution) of an unsaturated cyclic organic acid (e.g. one having a molecular weight of 500 to 1500D, for example a boronic acid conjugate) and a surfactant (e.g. a non-ionic surfactant, especially a Triton) . Such a solution may of course contain further solutes which would likewise be released when the material is contacted with water. The invention will now be described further with reference to the following non-limiting Examples. The drying conditions for the second reagent in Examples 2, 5 and 6 and for the solutoin precursor in Example 3 are as follows:
A vacuum drying oven or a freeze-drier with a programmable vacuum controller can be used. The apparatus should be set to approach a pressure of 7-10 mbar within 40-65 minutes. Depending on the number of tubes (amount of liquid) to be dried and the kind of freeze-dryer, the setting will vary. The settings may thus be varied so as to produce an even film of dried material on the plastic walls.
For a Heraeus Vacuum Drying oven (VT 6025) the following settings have been used (400-500 tubes) :
Temperature : 30°C Time to obtain P2 : 5 min P2 : 100 mBar Time to rest at P2 : 5 min
Time to obtain P3 : 5 min P3 : 50 mBar
Time to rest at P3 : 5 min
Time to obtain P4 : 5 min
P4 : 20 mBar
Time to rest at P4 : 5 min
Time to obtain P5 : 10 min P5 : 7 mBar Time to rest at P5 : 804 min
EXAMPLE 1 Two Solution Assay First Reagent
The first reagent comprises :
200mM Hepes buffer
50 mM glycine
18mM ZnCl2
30mM MgCl2
400mM NaCl
0.15% w/v Triton X-100
0.05% w/v NaN3 pH 8.12
The reagent is prepared by mixing ImL IM Hepes, 0.25 mL IM glycine, 2mL H20, 0.09 mL IM ZnCl2, 0.15 mL IM MgCl2, 0.4 mL 5M NaCl, 0.075 mL 10% Triton X-100 and 0.025 mL
10% NaN3. The pH is adjusted to 8.12 and water is added to 5 mL.
The first reagent may alternatively be made as follows: 24.6 mg zinc chloride is dissolved in 2.5 mL water. 233.8 mg sodium chloride, 61 mg magnesium chloride hexahydrate, 0.05 mL 10% sodium azide and 0.1 mL 10% Triton X-100 are dissolved in 2.5 mL water. The two solutions are then combined. 476.6 mg HEPES and 37.6 mg glycine are dissolved in 1.5 mL water and 0.4 mL 5M sodium hydroxide. This HEPES solution is then added to the zinc and Triton X-100 solution and the pH is adjusted to 8.1 and the volume to 10 mL.
Second Reagent
The second reagent comprises:
12.4% v/v formamide 0.32 mg/mL XC-DAPOL-CPBA 0.15% w/v Triton X-100 The reagent is prepared by mixing 0.11 mL formamide, 0.52 mL XC-DAPOL-CPBA (3.15 g/L in formamide) and water to 5mL. DMSO may be used in place of formamide.
Assay Procedure :
100 μL of the first reagent is mixed with 100 μL of the second reagent . The mixture is added to 5 μL blood and allowed to incubate for 2 minutes. A 25 μL aliquot is then placed on a glass fibre filter. 25 μL of a washing solution pH 9.1 (Example 4) is added and the result is read on a NycoCard® reader at 632 and 476- nm.
EXAMPLE 2 Solution and dried conjugate assay
First Reagent
The first reagent comprises:
lOOmM Hepes
25mM glycine
9mM ZnCl2
15mM MgCl2
200mM NaCl
0.1% w/v Triton X-100
0.05% w/v NaN3 pH 8.12
The reagent is prepared by mixing 1 mL IM Hepes, 0.25 mL 1 M glycine, 2 mL H20, 0.09 mL IM ZnCl2, 0.15 mL IM
MgCl2, 0.4 mL 5 M NaCl, 0.1 mL 10% Triton X-100 and 0.05 mL 10% NaN3. The pH is adjusted to 8.12 and water is added to 10 mL.
The first reagent may alternatively be made as follows: 12.3 mg zinc chloride is dissolved in 2.5 mL water. 116.9 mg sodium chloride, 30.5 mg magnesium chloride hexahydrate, 0.05 mL 10% sodium azide and 0.1 mL 10% Triton X-100 are dissolved in 2.5 mL water. The two solutions are then combined. 238.3 mg HEPES and 18.8 mg glycine are dissolved in 1.5 mL water and 0.2 mL 5M sodium hydroxide. This HEPES solution is then added to the zinc and Triton X-100 solution and the pH is adjusted to 8.1 and the volume to 10 mL.
Second Reagent (A) Solution Precursor
The solution precursor comprises
64.1% v/v methanol 0.23 mg/mL XC-DAPOL-CPBA 0.336% w/v Triton X-100 0.48 mM citric acid.
The solution precursor is prepared by dissolving XC- DAPOL-CPBA in methanol 0.36 mg/mL. 2 mL of this are mixed with 105 μL 10% Triton X-100, ImL water and 15 μL 0.1 M citric acid.
(B) Second Reagent
150 μL of the solution precursor is evaporated.
The solution precursor may alternatively comprise
20% v/v methanol
0.3-0.5 mg/mL XC-DAPOL-CPBA 0.34% w/v BSA
0.336% w/v Triton X-100 0.4-0.6 mM citric acid to pH 4.1
The solution precursor is prepared by dissolving XC- DAPOL-CPBA in methanol 2.5 mg/mL. 2 mL of the solution is mixed with 4.8 mL 0.7% Triton X-100 and 2 mL 0.5% w/v BSA is added and the pH is adjusted to .1 with 0.1 M citric acid (ca 50-60 μL) . Water is added to a volume of 10 mL. The amount of XC-DAPOL-CPBA used is adjusted to provide an optical density (OD) of 32.5 at 620 nm.
125 μL of this solution precursor is then vacuum dried to produce the second reagent .
Assay Procedure:
200 μL of the first reagent are mixed with the second reagent and then with 5 μL blood. The assay procedure is thereafter as in Example 1.
EXAMPLE 3
Dried buffer and liquid conjugate assay
(A) Solution Precursor
The first reagent comprises :
50 mM Glycinamide hydrochloride
10 mM ZnCl2 20 mM MgCl2
200 mM NaCl
0.1% w/v Triton X-100
0.05% w/v NaN3 pH 8.12
13.6 mg ZnCl2 are dissolved in 2.5 mL water. 116.9 mg
NaCl, 40.6 mg MgCl2 x 6 H20, 0.05 mL 10% w/v NaN3 and 0.1 mL 10% w/v Triton X-100 are dissolved in 2.5 mL water.
The two solutions are then mixed. 55.2 mg glycinamide is then dissolved in 1.5 mL water and 0.4 mL 5M NaOH and this solution is added to the zinc solution. The pH is adjusted to 8.1 and the volume to 10 mL.
(B) First Reagent 200 μL of the solution precursor is vacuum dried. Second Reagent
The BSA-containing solution referred to in Example 2 as the solution precursor is used in a liquid form.
Assay Procedure:
200 μL of the first reagent are mixed with the second reagent and then with 5 μL blood. The assay procedure is thereafter as in Example 1.
EXAMPLE 4 Washing Solution
The washing solution comprises
50mM morpholine 200 mM NaCl 0.5% w/v Triton X-100 0.1% w/v glycerol 0.05% w/v NaN3.
The solution is prepared by mixing the components, adjusting to pH 9.1 and adding water to achieve the desired concentration.
EXAMPLE 5
Solution and Dried Conjugate Assay
The materials for the assay are prepared as in Example 2 except that the solution precursor is prepared by dissolving the boronic acid conjugate in 0.5 mM NaOH to 0.25 mg/mL. This requires 10 to 30 minutes stirring. 2 mL of the solution is then mixed with 0.05 mL 10% Triton X-100 and stirred for a further 10 minutes. The pH is then reduced to about 4.5 by addition of 0.01 mL 0. IM citric acid. The assay is performed as in Example 2. EXAMPLE 6
Solution and Dried Conjugate Assay
The materials for the assay are prepared as in Example 2 except that the solution precursor is prepared by dissolving the boronic acid in 10 mM NaOH to 2.5 mg/mL. 2 mL of this are mixed with 4.8 mL 0.7% w/v Triton X- 100. 2 mL 0.5% w/v BSA is added and the pH is adjusted to 4.1 with 0.1 M citric acid (50-60 μL) . Water is added to a volume of 10 mL. The quantity of conjugate used is adjusted to provide an optical density at 620 nm of 32.5. The assay is performed as in Example 2.

Claims

Claims :
1. A kit for a glycated haemoglobin assay, said kit comprising: a porous membrane capable of retaining precipitated haemoglobin; a first reagent comprising zinc ions in aqueous basic solution or comprising a water soluble zinc compound; a second reagent comprising a chromophore-boronic acid conjugate; and optionally, an aqueous washing reagent; wherein at least one of the first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second reagent if liquid is acidic.
2. A kit as claimed in claim 1 wherein said first reagent comprises zinc ions in aqueous basic solution.
3. A kit as claimed in either of claims 1 and 2 wherein said second reagent contains a surfactant .
4. A kit as claimed in any one claims 1 to 3 wherein said second reagent is a dried material.
5. A kit as claimed in any one of claims 1 to 4 wherein said first reagent contains a surfactant .
6. A kit as claimed in any one claims 1 to 5 wherein at least one of said first and second reagents contains albumin.
7. A kit as claimed in any one of claims 1 to 6 wherein one of said first and second reagents is in liquid form in a container and the other of said first and second reagents is in dried form coated on a stopper appliable to said container.
8. A method for assaying a blood sample for glycated haemoglobin, said method comprising contacting a blood sample with a surfactant capable of lysing erythrocytes, a chromophore-boronic acid conjugate, and zinc ions in aqueous solution, allowing the sample to incubate, passing the incubated sample through a porous membrane capable of retaining precipitated haemoglobin, flushing the membrane to remove conjugate not coupled to haemoglobin, measuring light reflected from the membrane at wavelengths at which haemoglobin and the conjugate respectively absorb light, and comparing the measured reflected light intensities whereby to provide a indication of the proportion of haemoglobin in the blood sample which is glycated, characterised in that said conjugate and zinc ions are brought together by combining a first reagent comprising zinc ions in aqueous basic solution and a second reagent comprising a chromophore-boronic acid conjugate wherein at least one of said first and second reagents further comprises a surfactant capable of lysing erythrocytes, and wherein said second regent if liquid is acidic.
9. A water-soluble material produced by drying a solution of an unsaturated cyclic organic acid (e.g. one having a molecular weight of 500 to 1500D, for example a boronic acid conjugate) and a surfactant.
PCT/GB2002/001664 2001-04-24 2002-04-10 Haemoglobin assay Ceased WO2002086512A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/474,505 US7374943B2 (en) 2001-04-24 2002-04-10 Haemoglobin assay
DK02713068T DK1381869T3 (en) 2001-04-24 2002-04-10 hemoglobin
DE60227935T DE60227935D1 (en) 2001-04-24 2002-04-10 HEMOGLOBIN TEST PROCEDURE
EP02713068A EP1381869B1 (en) 2001-04-24 2002-04-10 Haemoglobin assay
CA002441929A CA2441929C (en) 2001-04-24 2002-04-10 Haemoglobin assay
JP2002583989A JP4184806B2 (en) 2001-04-24 2002-04-10 Hemoglobin assay
AU2002244858A AU2002244858B2 (en) 2001-04-24 2002-04-10 Haemoglobin assay
NO20034687A NO332622B1 (en) 2001-04-24 2003-10-20 Methods for glycated hemoglobin analysis and method for analysis of a blood sample for glycated hemoglobin.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110053.6A GB0110053D0 (en) 2001-04-24 2001-04-24 Assay
GB0110053.6 2001-04-24

Publications (2)

Publication Number Publication Date
WO2002086512A2 true WO2002086512A2 (en) 2002-10-31
WO2002086512A3 WO2002086512A3 (en) 2003-10-16

Family

ID=9913374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001664 Ceased WO2002086512A2 (en) 2001-04-24 2002-04-10 Haemoglobin assay

Country Status (14)

Country Link
US (1) US7374943B2 (en)
EP (1) EP1381869B1 (en)
JP (1) JP4184806B2 (en)
CN (1) CN100593117C (en)
AT (1) ATE403159T1 (en)
AU (1) AU2002244858B2 (en)
CA (1) CA2441929C (en)
DE (1) DE60227935D1 (en)
DK (1) DK1381869T3 (en)
ES (1) ES2309154T3 (en)
GB (1) GB0110053D0 (en)
NO (1) NO332622B1 (en)
PT (1) PT1381869E (en)
WO (1) WO2002086512A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1624307A3 (en) * 2004-08-03 2006-10-11 Axis-Shield Diagnostics Limited Assay for detecting glycated or glycosylated haemoglobin (HbA1c)
WO2014033258A1 (en) * 2012-08-31 2014-03-06 Axis-Shield Asa Glycated haemoglobin assay method
CN105241831A (en) * 2015-10-12 2016-01-13 山东博科生物产业有限公司 Stable good-interference resistance serum zinc detection reagent and detection method
CN115607691A (en) * 2022-11-01 2023-01-17 贵州威门药业股份有限公司 Relinqing granules with excellent antipyretic effect

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4034351B2 (en) 1996-04-25 2008-01-16 バイオアレイ ソリューションズ エルエルシー Light-controlled electrokinetic assembly of particle-proximal surfaces
DE60117556T2 (en) 2000-06-21 2006-11-02 Bioarray Solutions Ltd. MULTI-ANALYTIC MOLECULAR ANALYSIS THROUGH THE USE OF APPLICATION SPECIFIC RAPID PARTICLE ARRAYS
US9709559B2 (en) * 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US7262063B2 (en) 2001-06-21 2007-08-28 Bio Array Solutions, Ltd. Directed assembly of functional heterostructures
EP1463825B1 (en) 2001-10-15 2017-12-06 BioArray Solutions Ltd. Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection
JP3993169B2 (en) 2002-02-11 2007-10-17 アンタレス・ファーマ・インコーポレーテッド Intradermal syringe
US7526114B2 (en) 2002-11-15 2009-04-28 Bioarray Solutions Ltd. Analysis, secure access to, and transmission of array images
WO2005029705A2 (en) 2003-09-18 2005-03-31 Bioarray Solutions, Ltd. Number coding for identification of subtypes of coded types of solid phase carriers
CA2539824C (en) 2003-09-22 2015-02-03 Xinwen Wang Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules
CA2899287A1 (en) 2003-10-28 2005-05-12 Bioarray Solutions Ltd. Optimization of gene expression analysis using immobilized capture probes
WO2005045060A2 (en) 2003-10-29 2005-05-19 Bioarray Solutions, Ltd. Multiplexed nucleic acid analysis by fragmentation of double-stranded dna
US7848889B2 (en) 2004-08-02 2010-12-07 Bioarray Solutions, Ltd. Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification
JP5216328B2 (en) 2005-01-24 2013-06-19 アンタレス ファーマ インコーポレイテッド Pre-filled needle assist syringe jet injector
JP4957547B2 (en) * 2005-04-14 2012-06-20 パナソニック株式会社 Method for measuring hemoglobin derivative, reagent composition used therefor, measurement kit, analysis device, and analysis system
US8486629B2 (en) 2005-06-01 2013-07-16 Bioarray Solutions, Ltd. Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation
US7618792B2 (en) * 2006-01-06 2009-11-17 Bioarray Solutions Ltd. Multiplexed detection of anti-red cell alloantibodies
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2007131013A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Two-stage reconstituting injector
US8501495B2 (en) * 2007-05-03 2013-08-06 Equal Access To Scientific Excellence Sequential solid phase immunoassay including contact pad to limit conjugate flow during manufacture
EP2268342B1 (en) 2008-03-10 2015-09-16 Antares Pharma, Inc. Injector safety device
EP3581224A1 (en) 2008-08-05 2019-12-18 Antares Pharma, Inc. Multiple dosage injector
CN102612381B (en) 2009-03-20 2015-09-09 安塔瑞斯制药公司 Hazardous Reagent Injection System
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
WO2013134244A2 (en) 2012-03-06 2013-09-12 Antares Pharma, Inc. Prefilled syringe with breakaway force feature
KR20150011346A (en) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 Needle assisted jet injection administration of testosterone compositions
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
KR20140032221A (en) 2012-09-06 2014-03-14 삼성전자주식회사 Method for identifying glycated protein in a sample and device for the same
CN102998463A (en) * 2012-11-29 2013-03-27 英科新创(厦门)科技有限公司 Method for measuring glycosylated hemoglobin and kit
CN103076214B (en) * 2012-12-26 2015-03-11 宁波美康生物科技股份有限公司 Preparation method of glycosylated hemoglobin quality control
ES2969984T3 (en) 2013-02-11 2024-05-23 Antares Pharma Inc Needle-assisted jet injection device having reduced firing force
JP6030803B2 (en) 2013-03-11 2016-11-24 アンタレス・ファーマ・インコーポレーテッド Dose syringe with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
KR102186835B1 (en) * 2014-11-03 2020-12-04 주식회사 람다트 A cartridge of assay apparatus for in vitro diagnosis
CN104897907B (en) * 2015-05-21 2016-09-21 广东优尼德生物科技有限公司 A kind of test kit detecting glycolated hemoglobin and detection method thereof
CN105301261A (en) * 2015-10-12 2016-02-03 广州江元医疗科技有限公司 Kit for detecting HbAlc (Glycosylated Hemoglobin), and preparation method and using method of kit
CN106872377A (en) * 2015-12-10 2017-06-20 中国科学院大连化学物理研究所 Bicinchoninic acid is used for the quantitative detecting method of protein content in alginate material
CN105806820B (en) * 2016-05-11 2018-09-28 江南大学 A kind of continuous flow synthetic method of glycoprotein fluorescent probe molecule
ES2902649T3 (en) 2016-09-22 2022-03-29 Dxgen Corp Composition of reagent for measuring glycated hemoglobin and method for measuring glycated hemoglobin using the same
KR102029797B1 (en) * 2016-09-22 2019-10-08 주식회사 딕스젠 Reagent Composition for Detecting Glycated hemoglobin and Detection Method of Glycated hemoglobin Using Thereof
CN107255724A (en) * 2017-01-03 2017-10-17 深圳市惠安生物科技有限公司 Real-time test reagent device of glycosylated hemoglobin and preparation method thereof
CN107153121B (en) * 2017-04-12 2019-03-08 深圳市东邦生物医疗技术有限公司 Glycosylated hemoglobin, hemoglobin detection kit and its detection method
CN107356568A (en) * 2017-06-05 2017-11-17 天津友盼生物技术有限公司 A kind of detection method by principle of fluorescent quenching quick detection saccharification hemoglobin content
CN107290310A (en) * 2017-06-05 2017-10-24 天津三箭生物技术股份有限公司 Glycosylated hemoglobin detection kit（Fluorimetric Quenching Method）Preparation method
EP3726215A4 (en) 2017-12-12 2022-01-19 DxGen Corp. Silica nanoparticles for biomarker diagnosis and method for producing same
CN109655607B (en) * 2019-01-25 2021-02-23 广东菲鹏生物有限公司 Erythrocyte lysis reagent and application thereof
CN111537315B (en) * 2020-07-13 2020-10-02 天津德祥生物技术有限公司 Erythrocyte membrane separation liquid and erythrocyte membrane separation method
CN115825293B (en) * 2023-02-21 2023-10-13 艾康生物技术(杭州)有限公司 Kit for glycosylated hemoglobin test

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO890029D0 (en) * 1989-01-04 1989-01-04 Axis Research NEW MODIFIED PEPTIDES AND PROTEINS FOR IN VITRO DIAGNOSIS (DIABETES).
GB9024775D0 (en) 1990-11-14 1991-01-02 Axis Research Chemical compounds
DE4206932A1 (en) * 1992-03-05 1993-09-09 Boehringer Mannheim Gmbh IMMUNOLOGICAL METHOD FOR DETERMINING A HAEMOGLOBIN DERIVATIVE
EP0749583B1 (en) * 1994-03-11 2002-08-28 Abbott Laboratories Cyanide-free reagent and method for the determination of hemoglobin
US5631364A (en) * 1994-03-31 1997-05-20 Axis Biochemicals Asa Labelled boronic acid derivatives
FR2749853B1 (en) * 1996-06-12 1998-10-16 Rhone Poulenc Chimie IMPROVED FORMULATION BASED ON A HYDROXYL COMPOUND AND A COMPLEX AMPHIPHILIC COMPOUND USED IN PARTICULAR TO MODIFY THE RHEOLOGICAL PROPERTIES OF EMULSIONS
US6043097A (en) * 1997-12-05 2000-03-28 Bayer Corporation Reagent package

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1624307A3 (en) * 2004-08-03 2006-10-11 Axis-Shield Diagnostics Limited Assay for detecting glycated or glycosylated haemoglobin (HbA1c)
US7592182B2 (en) 2004-08-03 2009-09-22 Axis-Shield Diagnostics Limited Assay
WO2014033258A1 (en) * 2012-08-31 2014-03-06 Axis-Shield Asa Glycated haemoglobin assay method
CN105241831A (en) * 2015-10-12 2016-01-13 山东博科生物产业有限公司 Stable good-interference resistance serum zinc detection reagent and detection method
CN115607691A (en) * 2022-11-01 2023-01-17 贵州威门药业股份有限公司 Relinqing granules with excellent antipyretic effect
CN115607691B (en) * 2022-11-01 2024-04-09 贵州威门药业股份有限公司 Relinqing granule with excellent antipyretic effect

Also Published As

Publication number Publication date
EP1381869B1 (en) 2008-07-30
NO20034687L (en) 2003-10-20
JP2004529347A (en) 2004-09-24
ATE403159T1 (en) 2008-08-15
US7374943B2 (en) 2008-05-20
CN100593117C (en) 2010-03-03
CN1531654A (en) 2004-09-22
NO20034687D0 (en) 2003-10-20
EP1381869A2 (en) 2004-01-21
CA2441929C (en) 2009-04-07
CA2441929A1 (en) 2002-10-31
GB0110053D0 (en) 2001-06-13
DK1381869T3 (en) 2008-12-01
ES2309154T3 (en) 2008-12-16
NO332622B1 (en) 2012-11-19
AU2002244858B2 (en) 2007-05-24
PT1381869E (en) 2008-09-11
JP4184806B2 (en) 2008-11-19
US20040137641A1 (en) 2004-07-15
DE60227935D1 (en) 2008-09-11
WO2002086512A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
CA2441929C (en) Haemoglobin assay
AU2002244858A1 (en) Haemoglobin assay
EP0703453B1 (en) Method for the determination of creatinine and urinary protein
US4615972A (en) Stabilization of indicators for detecting enzyme activity
JP3088789B2 (en) Ion assay method and instrument
EP2857837A1 (en) Freeze-drying conjugate-construct for point-of-care testing immunochromatography, a kit for immunoassay using the same, and a method for analysis using the kit
EP1517996A2 (en) Test strip and method for determining concentration of creatinine in a body fluid
US5753455A (en) Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
AU617300B2 (en) Reagent and procedure for determining cations
US4440724A (en) Composition for detecting ketone bodies and method of preparation
JPS6142823B2 (en)
US4376828A (en) Bilirubin test kit
CN112268868A (en) Kit for determining calprotectin by latex immunoturbidimetry
CN115166263B (en) A kit and method for measuring glycated hemoglobin concentration
EP2318838B1 (en) High capacity solid phase
CN114112957B (en) Adiponectin determination kit and application thereof
Kadobayashi et al. Spectrophotometric determination of DNA binding protein, histone, with 3, 4, 5, 6-tetrafluoro-2-carboxyphenylfluorone and manganese (II)
US4030885A (en) Bilirubin determination
JP2522970B2 (en) Test piece for determination of creatinine in body fluid and method for producing the same
JP2522971B2 (en) Creatinine quantification test piece and its manufacturing method
Watson et al. Use of the Barbiturate-Mercury Reaction in Clinical Laboratory ‘Screening’for Barbiturate Poisoning
JPH06181762A (en) Labeled antibody composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002713068

Country of ref document: EP

Ref document number: 2002244858

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1422/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2441929

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002583989

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028087658

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002713068

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10474505

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002244858

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2002713068

Country of ref document: EP